Drug Database
Back to search

Belgium· BE-AMP-SAM663918-00

Nemluvio 30 mg

A nemolizumab product containing nemolizumab, registered in Belgium by Galderma International. The same ATC class is registered in 14 of our 19 countries.

ATC D11AH12

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedNemluvio 30 mgATCD11AH12REGISTER NO.BE-AMP-SAM663918-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nemolizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nemolizumab is registered in 14 of 19 countries.

Countries holding a registration under ATC D11AH12 (nemolizumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search nemolizumab products by name

Nemolizumab · ATC D11AH12

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nemolizumab costs, country by country.

Normalised to the WHO defined daily dose (0.8 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Nemolizumab · price per daily dose (0.8 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$67.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Nemolizumab
Manufacturer
Galderma International
Country
Belgium (BE)
ATC code
D11AH12
ATC class
Nemolizumab
Defined daily dose
0.8 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    7749815
  • be_apb
    4975983
    EUR 2013.37

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Nemolizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nemolizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Nemluvio
  • Liechtenstein · Nemluvio
  • Norway · Nemluvio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/125032f3-4c29-4bfe-a296-6bf8684a86d9
GET /v1/drugs/125032f3-4c29-4bfe-a296-6bf8684a86d9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder and solvent for solution for injection in pre-filled pen",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Nemluvio 30 mg",
  "name_fr": "Nemluvio 30 mg",
  "name_nl": "Nemluvio 30 mg",
  "amp_code": "SAM663918-00",
  "strengths": [
    "30.0000",
    "30.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Nemolizumab",
    "Sucrose"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Nemolizumab",
  "authorisation_numbers": [
    "EU/1/24/1901/003",
    "EU/1/24/1901/001",
    "EU/1/24/1901/002"
  ]
}
API referenceMCP serverPlans

See everything about nemolizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console